FLJ37512 Inhibitors
Inhibitors of FLJ37512 exert their effects by targeting various cellular processes and signaling pathways that are critical to the protein's function at synapses. These compounds disrupt key aspects of intracellular signaling and protein trafficking, which are pertinent to FLJ37512's role in the nervous system. For example, certain inhibitors target the peroxisome proliferator-activated receptors, altering lipid metabolism and inflammation, which subsequently interferes with synaptic function and inhibits FLJ37512 indirectly. Others inhibit the activity of glycogen synthase kinase-3, a kinase implicated in neurodevelopment and synaptic plasticity, thus potentially altering FLJ37512's phosphorylation state and function. Additionally, some compounds bind to glucose and mannose residues, affecting glycoprotein folding and trafficking, which may prevent FLJ37512 from reaching the synapse or disrupt its function there.
Furthermore, the mechanisms of FLJ37512 inhibition also involve interference with protein kinase C, which modulates neurotransmitter release and synaptic plasticity. The altered phosphorylation of synaptic proteins, including FLJ37512, can disrupt its functional role at synapses. Agents that inhibit vesicle formation in the Golgi apparatus or N-linked glycosylation can mislocalize FLJ37512 or compromise its activity by preventing essential post-translational modifications. Calcium-calmodulin signaling inhibitors and microtubule polymerization disruptors further inhibit the functional activity of FLJ37512 by affecting its regulation and transport to synaptic sites.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palmitoylethanolamide | 544-31-0 | sc-202754 sc-202754A sc-202754B sc-202754C sc-202754D | 10 mg 50 mg 500 mg 1 g 10 g | $78.00 $238.00 $2050.00 $3274.00 $16330.00 | ||
Palmitoylethanolamide engages with peroxisome proliferator-activated receptors (PPAR-α) that regulate gene expression related to lipid metabolism and inflammation. FLJ37512, being a synaptic protein, its activity could be affected by changes in lipid composition and inflammatory processes, potentially leading to alterations in synaptic function and indirect inhibition of FLJ37512. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride modulates glycogen synthase kinase-3 (GSK-3) activity. GSK-3 is involved in numerous signaling pathways, including those related to neurodevelopment and synaptic plasticity. Inhibition of GSK-3 could alter the phosphorylation state and function of proteins such as FLJ37512, which is associated with synaptic function, thereby indirectly inhibiting FLJ37512. | ||||||
Concanavalin A | 11028-71-0 | sc-203007 sc-203007A sc-203007B | 50 mg 250 mg 1 g | $117.00 $357.00 $928.00 | 17 | |
Concanavalin A is a lectin that binds to glucose and mannose residues, potentially interfering with glycoproteins' proper folding and trafficking. As FLJ37512 is a contactin-associated protein, its function could be dependent on glycosylation and cell surface localization. Binding of Concanavalin A may disrupt FLJ37512 trafficking to the synapse, indirectly leading to its functional inhibition. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in the modulation of neurotransmitter release and synaptic plasticity. PKC activation could result in altered phosphorylation states of synaptic proteins including FLJ37512, thereby potentially disrupting its functional role at the synapse and indirectly inhibiting its activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), which is essential for vesicle formation in the Golgi apparatus. By inhibiting ARF, Brefeldin A disrupts protein trafficking, including that of membrane proteins like FLJ37512, possibly leading to its mislocalization and subsequent functional inhibition. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, a post-translational modification crucial for the function and localization of many membrane proteins. FLJ37512's activity could be compromised by such an inhibition, as proper glycosylation may be necessary for its synaptic role, leading to indirect inhibition of its function. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
W-7 is a calmodulin antagonist that inhibits calcium-calmodulin dependent processes. Since FLJ37512 is implicated in synaptic connections, its function might be regulated by calcium-calmodulin signaling pathways. Inhibition of these pathways by W-7 could indirectly lead to the functional inhibition of FLJ37512. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $98.00 $315.00 $2244.00 $4396.00 $17850.00 $34068.00 | 3 | |
Colchicine disrupts microtubule polymerization, which is critical for axonal transport. Proteins like FLJ37512 that are involved in synaptic function may rely on axonal transport for their localization and activity. Disruption of microtubules by colchicine could therefore inhibit the proper trafficking of FLJ37512, indirectly leading to its functional inhibition. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with ribosomal translocation. Although it is a general inhibitor, its effect on protein synthesis includes proteins involved in synaptic function like FLJ37512. Continuous inhibition of protein synthesis could lead to a depletion of FLJ37512 in the synapse, indirectly inhibiting its function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing intracellular levels of cAMP. Elevated cAMP may alter the phosphorylation state and activity of various proteins, including those associated with the synapse where FLJ37512 is localized. Changes in synaptic protein function due to forskolin's action could lead to an indirect inhibition of FLJ37512's activity. | ||||||